Posted by Michael Wonder on 29 Sep 2024
Enterprise Therapeutics granted rare paediatric disease designation in the US for novel cystic fibrosis investigational therapy ETD001
26 September 2024 - ETD001 is a novel, first in class blocker of the epithelial sodium channel aimed at treating people with cystic fibrosis without current effective therapies.
Enterprise Therapeutics today announced its novel cystic fibrosis investigational therapy, ETD001, has been granted ‘rare paediatric disease designation’ in the US by the FDA.
